How do I buy Generate Biomedicines, Inc. Common Stock (GENB) stock?

Buying Generate Biomedicines, Inc. Common Stock (GENB) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "GENB", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy GENB by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for GENB on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Generate Biomedicines, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Generate Biomedicines, Inc. Common Stock (GENB) pay dividends?

At the moment, Generate Biomedicines, Inc. Common Stock (GENB) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track GENB's performance via the price chart in the Gotrade app.

Is buying GENB on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy GENB?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if GENB is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Generate Biomedicines, Inc. Common Stock (GENB) Stock Price Today & Analysis

% positive news of 7 articles

published over the past 14 days

Latest news

Proactive Investors

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

NeutralGENBAugust 25, 2026

Proactive InvestorsNeutral

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

GENB

The Motley Fool

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

NeutralGENBAugust 5, 2026

The Motley FoolNeutral

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

GENB

The Motley Fool

Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?

NeutralGENBJuly 11, 2026

The Motley FoolNeutral

Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?

GENB

The Motley Fool

About Generate Biomedicines, Inc. Common Stock

Generate Biomedicines is a clinical-stage generative biology company pioneering the application of artificial intelligence in biotechnology, drug design, and development. The company’s vision is to program biology to generate optimal therapeutics with meaningful impact on human health. Central to this vision is the Generate Platform, a therapeutic area- and protein modality-agnostic system that integrates computational innovation with scalable biohardware to address challenges beyond the reach of traditional technologies. The platform operates through a tightly integrated design–build–test–learn loop, enabling the creation of proprietary, therapeutically relevant data and differentiated molecular solutions for complex biological targets.

SectorHealthcare

IndustryBiotechnology

Employees312

CEOMr. Michael T. Nally M.B.A.

IPO DateFeb 27, 2026

HeadquartersSomerville, MA

Key Executives

Name	Title	Year Born
Dr. Noubar B. Afeyan Ph.D.	Co-founder & Independent Chair of the Board	1963
Mr. Michael T. Nally M.B.A.	CEO & Director	1976
Dr. Jason E. Silvers J.D., M.D.	President & CFO	1972
Dr. Gevorg Grigoryan Ph.D.	Co-Founder & CTO	1981
Ms. Molly Gibson Ph.D.	Co-Founder	—
Dr. Aarif Khakoo M.B.A., M.D.	Chief Scientific Officer	1971
Mr. Sean B. W. Martin J.D.	Secretary, Chief Legal Officer & General Counsel	1963
Ms. Beth Grous	Chief People Officer	1968
Dr. Daria Hazuda Ph.D.	Senior Vice President of Discovery Strategy	—
Mr. Sahm Nasseri M.B.A.	Senior Vice President of Business Development & Strategy	1985

Fundamentals

Valuation

Market cap$1.94B

Price-to-sales ratio64.35

Price-to-book value4.50

Price-earnings ratio-8.20

Return on EquityN/A

Return on SalesN/A

Return on AssetsN/A

PEG ratioN/A

Earnings Per Share

Earnings Per Share$-7.57

Income Statement

Average volume1,637,914

EBITDA$-182.74M

1 year high (52w)$22.67

1 year low (52w)$11.00

Dividend

Ex dividend dateN/A

Dividend amount$0.00

Dividend yield0.00%

Last payment dateN/A

Dividend yield (TTM)N/A

Next earnings reportN/A

Solvency

Debt-to-equity ratioN/A

Technicals

OscillatorsSell5 Indicators

Moving AveragesStrong Sell10 Indicators

What the experts say

1 Wall Street Analyst Ratings

BUY

100% Buy

0% Hold

0% Sell

Target price

$30.00

Est return

103.11%

HC Wainwright & Co.

Mitchell S. Kapoor

Buy

Target price

$30.00

Est return

102.98%

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026		+0.0	+2.7	-5.1	-0.2	+30.1	-15.2	+6.5	-4.1

Generate Biomedicines, Inc. Common Stock (GENB) Stock

Fundamentals

Recent news

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?

Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Technicals

Analyst Ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?

Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut

Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut

Drug developer Generate Biomedicines raises $400 million in US IPO

Drug developer Generate Biomedicines raises $400 million in US IPO

Generate Biomedicines aims to raise $425 million in US IPO

Generate Biomedicines aims to raise $425 million in US IPO

About Generate Biomedicines, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Solvency

Technicals

What the experts say

Seasonality

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade